A randomized controlled multicentre open-label parallel arm study to assess the non-inferiority of the safety of bevacizumab compared to ranibizumab (allocation 4:1) administered by intravitreal injection in patients with macular degeneration or other exudative not age-related macular.

Trial Profile

A randomized controlled multicentre open-label parallel arm study to assess the non-inferiority of the safety of bevacizumab compared to ranibizumab (allocation 4:1) administered by intravitreal injection in patients with macular degeneration or other exudative not age-related macular.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Mar 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Ranibizumab
  • Indications Age-related macular degeneration; Choroidal neovascularisation; Diabetic macular oedema
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top